Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model

Thrombosis and Haemostasis

Volumn 115, Issue 2, 2016, Pages 271-284

  Honickel, Markus ^a   Maron, Benjamin ^a   Van Ryn, Joanne ^b   Braunschweig, Till ^a   ten Cate, Hugo ^c   Spronk, Henri M H ^c   Rossaint, Rolf ^a   Grottke, Oliver ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Anticoagulants; aPCC; Dabigatran; FEIBA; Idarucizumab; Polytrauma; Reversal

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; DABIGATRAN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; IDARUCIZUMAB; MONOCLONAL ANTIBODY; PROTHROMBIN COMPLEX CONCENTRATES; THROMBIN; VITAMIN K GROUP;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTERIAL PRESSURE; ARTICLE; BLEEDING; BLOOD GAS ANALYSIS; CONTROLLED STUDY; FEMALE; FEMUR FRACTURE; HEMODYNAMICS; HUMAN; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MICROSCOPY; MIDDLE AGED; MULTIPLE TRAUMA; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; CALIBRATION; CHEMICALLY INDUCED; CHEMISTRY; CYTOLOGY; FEMORAL FRACTURES; HEMORRHAGE; HEMOSTASIS; METABOLISM; ORAL DRUG ADMINISTRATION; PIG; PROTHROMBIN TIME; RANDOMIZATION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOELASTOGRAPHY; TIME FACTOR;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; AREA UNDER CURVE; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; BLOOD PLATELETS; CALIBRATION; DABIGATRAN; FEMORAL FRACTURES; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMODYNAMICS; HEMORRHAGE; HEMOSTASIS; MALE; MULTIPLE TRAUMA; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; PROTHROMBIN TIME; RANDOM ALLOCATION; SWINE; THROMBELASTOGRAPHY; THROMBIN; TIME FACTORS; VITAMIN K;

EID: 84957577892     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-03-0266     Document Type: Article

References (44)

1. Miller CS, Grandi SM, Shimony A et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110: 453–460.
2. Gonsalves WI, Pruthi RK, Patnaik MM. The new oral anticoagulants in clinical practice. Mayo Clin Proc 2013; 88: 495–511.
3. Pradaxa 110 mg hard capsules–Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/20760#INDICATIONS. Accessed September 18, 2014.
4. Levy JH, Faraoni D, Spring JL et al. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013; 118: 1466–1474.
5. Maegele M, Lefering R, Yucel N et al. Early coagulopathy in multiple injury: an analysis from the German Trauma Registry on 8724 patients. Injury 2007; 38: 298–304.
6. Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care 2007; 13: 680–685.
7. Holbrook A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e152S-184S.
8. Spahn DR, Bouillon B, Cerny V et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013; 17: R76.
9. Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625–651.
10. Khadzhynov D, Wagner F, Formella S et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013; 109: 596–605.
11. Stangier J, Rathgen K, Stahle H et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an openlabel, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259–268.
12. ClinicalTrials.gov. Reversal of Dabigatran Anticoagulant Effect With Idarucizumab. Available at: http://www.clinicaltrials.gov/ct2/show/NCT02104947?term=nct02104947&rank=1. Accessed November 21, 2014.
13. Pollack CV, Jr., Reilly PA, Eikelboom J et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; Epub ahead of print.
14. Schiele F, van Ryn J, Canada K et al. A specific antidote for dabigatran: functional and structural characterisation. Blood 2013; 121: 3554–3562.
15. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost 2015; 113: 931–942.
16. Lu G, DeGuzman FR, Hollenbach SJ et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446–451.
17. Grottke O, van Ryn J, Spronk HM et al. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care 2014; 18: R27.
18. Lambourne MD, Eltringham-Smith LJ, Gataiance S et al. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost 2012; 10: 1830–1840.
19. Pragst I, Zeitler SH, Doerr B et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012; 10: 1841–1848.
20. Guide for the Care and Use of Laboratory Animals. 7th ed. Institute of Laboratory Animal Resources, Commission of Life Sciences, National Research Council: Washington DC: National Academy Press; 1996.
21. Baxter Healthcare Ltd. FEIBA 500 U powder and solvent for solution for infusion. Available at: https://www.medicines.org.uk/emc/medicine/30169. Accessed June 21, 2015.
22. Baker TA, Romero J, Bach HHt et al. Systemic release of cytokines and heat shock proteins in porcine models of polytrauma and hemorrhage. Crit Care Med 2012; 40: 876–885.
23. Grottke O, Braunschweig T, Philippen B et al. A new model for blunt liver injuries in the swine. Eur Surg Res 2010; 44: 65–73.
24. Spronk HM, Dielis AW, De Smedt E et al. Assessment of thrombin generation II: Validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory. Thromb Haemost 2008; 100: 362–364.
25. van Ryn J, Kink-Eiband M, Kuritsch I et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 2004; 44: 777–784.
26. Grottke O, Braunschweig T, Zimmermann L et al. Recombinant factor VIIa reduces bleeding after blunt liver injury in coagulopathic, hypofibrinogenaemic pigs. Br J Anaesth 2010; 105: 789–797.
27. Zhou W, Schwarting S, Illanes S et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594–3599.
28. van Ryn J, Schurer J, Kink-Eiband M et al. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Anesthesiology 2014; 120: 1429–1440.
29. Herzog E, Kaspereit FJ, Krege W et al. Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model. Thromb Res 2014; 134: 729–736.
30. Hess JR, Brohi K, Dutton RP et al. The coagulopathy of trauma: a review of mechanisms. J Trauma 2008; 65: 748–754.
31. Brohi K, Cohen MJ, Ganter MT et al. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma 2008; 64: 1211–1217.
32. Dunbar NM, Chandler WL. Thrombin generation in trauma patients. Transfusion 2009; 49: 2652–2660.
33. Grottke O, Braunschweig T, Spronk HM et al. Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood 2011; 118: 1943–1951.
34. Dusel CH, Grundmann C, Eich S et al. Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates. Blood Coagul Fibrinolysis 2004; 15: 405–411.
35. Schulman S, Ritchie B, Goy JK et al. Activated prothrombin complex concentrate for dabigatran-associated bleeding. Br J Haematol 2014; 164: 308–310.
36. Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 2013; 41: e42–46.
37. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 2012; 10: 1478–1485.
38. Marlu R, Hodaj E, Paris A et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217–224.
39. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573–1579.
40. Herrmann R, Thom J, Wood A et al. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost 2014; 111: 989–995.
41. Honickel M, Treutler S, van Ryn J et al. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost 2015; 113: 728–740.
42. Curvers J, van de Kerkhof D, Stroobants AK et al. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful? Am J Clin Pathol 2012; 138: 551–558.
43. Davenport RA, Brohi K. Coagulopathy in trauma patients: importance of thrombocyte function? Curr Opin Anaesthesiol 2009; 22: 261–266.
44. Schochl H, Voelckel W, Schlimp CJ. Management of traumatic haemorrhage–the European perspective. Anaesthesia 2015; 70 (Suppl 1): 102–107, e35–37.